The company's dropping revenue and EBIT loss reflect negativ...
The company's dropping revenue and EBIT loss reflect negatively on its ability to service its debt. The balance sheet is somewhat strained, requiring careful monitoring. There is a concern over negative free cash flow, making the company's position risky.
We Think Luoxin Pharmaceuticals Group Stock (SZSE:002793) Has A Fair Chunk Of Debt
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment